OBJECTIVE: Fibroblast-like synoviocytes (FLS) participate in joint inflammation and damage in rheumatoid arthritis (RA) and its animal models. The purpose of this study was to define the importance of KCa1.1 (BK, Maxi-K, Slo1, KCNMA1) channel expression and function in FLS and to establish these channels as potential new targets for RA therapy. METHODS: We compared KCa1.1 expression levels in FLS from rats with pristane-induced arthritis (PIA) and in FLS from healthy rats. We then used ex vivo functional assays combined with small interfering RNA-induced knockdown, overexpression, and functional modulation of KCa1.1 in PIA FLS. Finally, we determined the effectiveness of modulating KCa1.1 in 2 rat models of RA, moderate PIA and severe collagen-induced arthritis (CIA). RESULTS: We found that PIA FLS expressed the KCa1.1 channel as their major potassium channel, as has been found in FLS from patients with RA. In contrast, FLS from healthy rats expressed fewer of these channels. Inhibiting the function or expression of KCa1.1 ex vivo reduced proliferation and invasive properties of, as well as protease production by, PIA FLS, whereas opening native KCa1.1 or overexpressing the channel enhanced the invasiveness of both FLS from rats with PIA and FLS from healthy rats. Treatment with a KCa1.1 channel blocker at the onset of clinical signs stopped disease progression in the PIA and CIA models, reduced joint and bone damage, and inhibited FLS invasiveness and proliferation. CONCLUSION: Our results demonstrate a critical role of KCa1.1 channels in the regulation of FLS invasiveness and suggest that KCa1.1 channels represent potential therapeutic targets in RA.
OBJECTIVE: Fibroblast-like synoviocytes (FLS) participate in joint inflammation and damage in rheumatoid arthritis (RA) and its animal models. The purpose of this study was to define the importance of KCa1.1 (BK, Maxi-K, Slo1, KCNMA1) channel expression and function in FLS and to establish these channels as potential new targets for RA therapy. METHODS: We compared KCa1.1 expression levels in FLS from rats with pristane-induced arthritis (PIA) and in FLS from healthy rats. We then used ex vivo functional assays combined with small interfering RNA-induced knockdown, overexpression, and functional modulation of KCa1.1 in PIA FLS. Finally, we determined the effectiveness of modulating KCa1.1 in 2 rat models of RA, moderate PIA and severe collagen-induced arthritis (CIA). RESULTS: We found that PIA FLS expressed the KCa1.1 channel as their major potassium channel, as has been found in FLS from patients with RA. In contrast, FLS from healthy rats expressed fewer of these channels. Inhibiting the function or expression of KCa1.1 ex vivo reduced proliferation and invasive properties of, as well as protease production by, PIA FLS, whereas opening native KCa1.1 or overexpressing the channel enhanced the invasiveness of both FLS from rats with PIA and FLS from healthy rats. Treatment with a KCa1.1 channel blocker at the onset of clinical signs stopped disease progression in the PIA and CIA models, reduced joint and bone damage, and inhibited FLS invasiveness and proliferation. CONCLUSION: Our results demonstrate a critical role of KCa1.1 channels in the regulation of FLS invasiveness and suggest that KCa1.1 channels represent potential therapeutic targets in RA.
Authors: Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy Journal: Toxicon Date: 2011-08-12 Impact factor: 3.033
Authors: Tanja C A Tolboom; Annette H M van der Helm-Van Mil; Rob G H H Nelissen; Ferdinand C Breedveld; René E M Toes; Tom W J Huizinga Journal: Arthritis Rheum Date: 2005-07
Authors: Christine Beeton; Heike Wulff; Nathan E Standifer; Philippe Azam; Katherine M Mullen; Michael W Pennington; Aaron Kolski-Andreaco; Eric Wei; Alexandra Grino; Debra R Counts; Ping H Wang; Christine J LeeHealey; Brian S Andrews; Ananthakrishnan Sankaranarayanan; Daniel Homerick; Werner W Roeck; Jamshid Tehranzadeh; Kimber L Stanhope; Pavel Zimin; Peter J Havel; Stephen Griffey; Hans-Guenther Knaus; Gerald T Nepom; George A Gutman; Peter A Calabresi; K George Chandy Journal: Proc Natl Acad Sci U S A Date: 2006-11-06 Impact factor: 11.205
Authors: R J Large; M A Hollywood; G P Sergeant; K D Thornbury; S Bourke; J R Levick; N G McHale Journal: Am J Physiol Cell Physiol Date: 2010-08-18 Impact factor: 4.249
Authors: Stephanie Lefèvre; Anette Knedla; Christoph Tennie; Andreas Kampmann; Christina Wunrau; Robert Dinser; Adelheid Korb; Eva-Maria Schnäker; Ingo H Tarner; Paul D Robbins; Christopher H Evans; Henning Stürz; Jürgen Steinmeyer; Steffen Gay; Jürgen Schölmerich; Thomas Pap; Ulf Müller-Ladner; Elena Neumann Journal: Nat Med Date: 2009-11-08 Impact factor: 53.440
Authors: Mark R Tanner; Michael W Pennington; Teresina Laragione; Pércio S Gulko; Christine Beeton Journal: FASEB J Date: 2017-04-20 Impact factor: 5.191
Authors: Mark R Tanner; Rajeev B Tajhya; Redwan Huq; Elizabeth J Gehrmann; Kathia E Rodarte; Mustafa A Atik; Raymond S Norton; Michael W Pennington; Christine Beeton Journal: Clin Immunol Date: 2017-04-04 Impact factor: 3.969
Authors: Mark R Tanner; Michael W Pennington; Brayden H Chamberlain; Redwan Huq; Elizabeth J Gehrmann; Teresina Laragione; Pércio S Gulko; Christine Beeton Journal: J Pharmacol Exp Ther Date: 2018-02-16 Impact factor: 4.030
Authors: Zoltán Pethő; Mark R Tanner; Rajeev B Tajhya; Redwan Huq; Teresina Laragione; Gyorgy Panyi; Pércio S Gulko; Christine Beeton Journal: Arthritis Res Ther Date: 2016-05-10 Impact factor: 5.156
Authors: Rajeev B Tajhya; Xueyou Hu; Mark R Tanner; Redwan Huq; Natee Kongchan; Joel R Neilson; George G Rodney; Frank T Horrigan; Lubov T Timchenko; Christine Beeton Journal: Cell Death Dis Date: 2016-10-20 Impact factor: 8.469
Authors: Mark R Tanner; Michael W Pennington; Satendra S Chauhan; Teresina Laragione; Pércio S Gulko; Christine Beeton Journal: Arthritis Res Ther Date: 2019-01-07 Impact factor: 5.156